Pricing Pills: When Uncle Sam Steps In

November 30, 2023
You must provide your professional email address to view this content.

As the U.S. healthcare system faces political pressure to improve affordability, regulatory risks for the pharmaceutical and insurance sectors are omnipresent. The ongoing negotiations and legislative changes, particularly those impacting drug pricing, could have important impacts on the profitability and operational strategies of major pharma players. Investors will need to adjust their pricing assumptions under different regulator scenarios, and on a drug-by-drug basis, when analyzing drug makers’ future revenue streams.

Disclaimer / Securities Disclosure

SECURITIES DISCLOSURE
The author(s) of this research note do (does) not personally hold a any position in any of the above-mentioned securities.
Nordis Capital (SMS’ sister company) does hold a position in Johnson & Johnson its ESG funds.

DISCLAIMER
© Sustainable Market Strategies, a division of SMS Financial Technologies inc. Redistribution prohibited without prior consent. This report has been prepared by Sustainable Market Strategies mainly for distribution to market professionals and institutional investors. It should not be considered as investment advice or a recommendation to purchase any particular security, strategy, or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.